Prognostic predictors in patients with cardiopulmonary arrest: A novel equation for evaluating the 30-day mortality

Imamura, Shun-ichi; Miyata, Masaaki; Tagata, Kento; Yokomine, Tatsuo; Ohmure, Kenta; Kawasoe, Mariko; Otsuji, Hideaki; Chaen, Hideto; Oketani, Naoya; Ogawa, Masanori; Nakamura, Kentaro; Yoshino, Satoshi; Kakihana, Yasuyuki; Ohishi, Mitsuru

doi:10.1016/j.jjcc.2023.01.006

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of all patients, those who underwent successful Impella implantation for the treatment of AMI-CS between January 2020 and December 2021 were included in this analysis. Patients with out-of-hospital cardiac arrest were excluded given the significant impact of pre-hospital cardiopulmonary resuscitation on mortality [ 11 ]. Patients without revascularization during the index hospitalization were excluded because of the clear survival benefit of early revascularization [ 12 ].…”

Section: Methodsmentioning

confidence: 99%

Sex-Related Differences in Short-Term Prognosis in Patients with Acute Myocardial Infarction-Related Cardiogenic Shock Receiving Impella Support in Japan: From the J-PVAD Registry

et al. 2023

View full text Add to dashboard Cite

Background and Objectives: Sex-specific outcome in patients with acute myocardial infarction-related cardiogenic shock (AMI-CS) receiving temporary mechanical circulatory support remains controversial. Materials and Methods: Patients with AMI-CS who received Impella support were prospectively enrolled in the Japanese registry for Percutaneous Ventricular Assist Device. Patients enrolled between January 2021 and December 2022 were considered to be eligible. Patients with out-of-hospital cardiac arrest and those without revascularization were excluded. The sex disparity in the 30-day survival after the initiation of Impella support was evaluated. Results: A total of 924 patients (median age 73 years; 21% female) were included. Female patients were older and had a smaller physiques than male patients (p < 0.05 for both). Female sex was significantly associated with a higher 30-day mortality after adjustment for four other potential confounders with a hazard ratio of 1.365 (95% confidence interval 1.026–1.816, p = 0.0324). In the female cohort, patients who received Impella prior to revascularization (N = 138) had a greater survival rate compared to those who received Impella after revascularization (68.1% versus 44.8%, p = 0.0015). Conclusions: Among the patients with AMI-CS who received Impella support and underwent revascularization, female sex was independently associated with a lower 30-day survival. For female patients, early initiation of Impella support prior to revascularization may improve their clinical outcomes.

show abstract

Section: Methodsmentioning

confidence: 99%